Drugs / Hepatitis B Virus Vaccine (Recombinant)
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03110757 Comparator | May 2018 → Nov 2019 | intestinal schistosomiasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hepatitis B Virus Vaccine (Recombinant) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03110757 ↗ |
| Known as | Euvax B | “Euvax B Hepatitis B vaccine (n=12)” NCT03110757 ↗ |
| Modality | Vaccine | “A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.” NCT03110757 ↗ |
| Route | Intramuscular | “Each participant received 3 intramuscular injections of study product” PMID 36996185 ↗ Mar 2023 |